4-[4-(1-tert-Butyl-5-isopropyl-1H-pyrazol-3-yl)-4-oxo-butyryl]-benzoic acid methyl ester | 187402-72-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[4-(1-tert-Butyl-5-isopropyl-1H-pyrazol-3-yl)-4-oxo-butyryl]-benzoic acid methyl ester
• 英文别名: Methyl 4-[4-(1-tert-butyl-5-propan-2-ylpyrazol-3-yl)-4-oxobutanoyl]benzoate
• CAS: 187402-72-8
• 化学式: C₂₂H₂₈N₂O₄
• 分子量: 384.475
• InChiKey: LRESRVSPKXHQPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  78.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[4-(1-tert-Butyl-5-isopropyl-1H-pyrazol-3-yl)-4-oxo-butyryl]-benzoic acid methyl ester 在 sodium hydroxide 、 ammonium acetate 作用下， 以 甲醇 为溶剂， 反应 6.0h， 生成 4-[5-(1-tert-Butyl-5-isopropyl-1H-pyrazol-3-yl)-1H-pyrrol-2-yl]-benzoic acid
  参考文献：
  名称：

  Novel retinoic acid receptor α agonists: syntheses and evaluation of pyrazole derivatives

  摘要：

  We have designed and synthesized a series of pyrazole derivatives as candidate retinoic acid receptor (RAR) agonists. One of them, 4-[5-(1, 5-diisopropyl-1H-3-pyrazolyl)-1H-2-pyrrolyl]benzoic acid (11b), which possesses a 2,5-disubstituted pyrrole moiety, showed selective transactivation activity for the RAR alpha receptor, and had highly potent cell-differentiating activity on HL-60 cells. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00066-4
• 作为产物：
  描述：

  1-甲氧基-5-甲基己烷-2,4-二酮 在 manganese(IV) oxide 、 3-苄基羟乙基甲基噻唑氯化锂 、 三溴化硼 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.17h， 生成 4-[4-(1-tert-Butyl-5-isopropyl-1H-pyrazol-3-yl)-4-oxo-butyryl]-benzoic acid methyl ester
  参考文献：
  名称：

  Novel retinoic acid receptor α agonists: syntheses and evaluation of pyrazole derivatives

  摘要：

  We have designed and synthesized a series of pyrazole derivatives as candidate retinoic acid receptor (RAR) agonists. One of them, 4-[5-(1, 5-diisopropyl-1H-3-pyrazolyl)-1H-2-pyrrolyl]benzoic acid (11b), which possesses a 2,5-disubstituted pyrrole moiety, showed selective transactivation activity for the RAR alpha receptor, and had highly potent cell-differentiating activity on HL-60 cells. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00066-4

文献信息

• Heterocycle-containing carboxylic acid derivative and drug containing the same
  申请人：Eisai Co. Ltd.

  公开号：US20020032202A1

  公开（公告）日：2002-03-14

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): 1 wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR 6 ═CR 7 — in which R 6 and R 7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  描述了一种含有杂环的羧酸衍生物，其化学式如下（I）：1其中A代表含有至少一个氮原子和可能具有取代基的杂芳基团，B代表例如杂芳烷基团，—CONH—基团或由公式—CR6═CR7—所表示的基团，其中R6和R7代表H、低碳基团或类似物，D代表芳基团、杂芳基团或类似物，n1代表0或1，M代表例如羟基或低碳氧基团；或其生理上可接受的盐。作为替代视黄酸的视黄酸相关化合物，它可以提供预防和/或治疗各种疾病的方法。
• Heterocycl-containing carboxylic acid derivative and drug containing the same
  申请人：Eisai Co. Ltd.

  公开号：US20020103234A1

  公开（公告）日：2002-08-01

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): 1 wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a —CONH— group or a group represented by the formula —CR 6 ═CR 7 — in which R 6 and R 7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  描述了一种含杂环的羧酸衍生物，其化学式为（I）：1，其中A代表例如至少含有一个氮原子并且可能具有取代基的杂芳基团，B代表例如杂芳烃基团，-CONH-基团或由式子-CR6═CR7-表示的基团，其中R6和R7代表H、低碳基或类似物，D代表芳烃基团、杂芳烃基团或类似物，n1代表0或1，M代表例如羟基或低碳氧基基团；或其生理上可接受的盐。作为替代视黄酸的视黄酸相关化合物，它可以提供预防和/或治疗各种疾病的方法。
• HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME
  申请人：Eisai Co., Ltd.

  公开号：EP0838453A1

  公开（公告）日：1998-04-29

  Described is a heterocycle-containing carboxylic acid derivative represented by the following formula (I): wherein A represents, for example, a heteroaryl group which contains at least one nitrogen atom and may have a substituent, B represents, for example, a heteroarylene group, a -CONH- group or a group represented by the formula -CR6=CR7- in which R6 and R7 represents H, a lower alkyl group or the like, D represents an arylene group, a heteroarylene group or the like, n1 stands for 0 or 1, M represents, for example, a hydroxyl group or a lower alkoxy group; or a physiologically acceptable salt thereof. As a retinoic-related compound replacing retinoic acid, it permits the provision of a preventive and/or therapeutic for various diseases.

  所述的是由下式(I)代表的含杂环的羧酸衍生物： 其中 A 代表例如含有至少一个氮原子并可具有取代基的杂芳基，B 代表例如杂芳基、-CONH- 基团或由式 -CR6=CR7- 代表的基团，其中 R6 和 R7 代表 H、低级烷基或类似基团，D 代表芳基、杂芳基或类似基团，n1 代表 0 或 1，M 代表例如羟基或低级烷氧基；或其生理学上可接受的盐。作为替代维甲酸的维甲酸相关化合物，它可以预防和/或治疗各种疾病。
• US5977108A
  申请人：——

  公开号：US5977108A

  公开（公告）日：1999-11-02
• US6329402B1
  申请人：——

  公开号：US6329402B1

  公开（公告）日：2001-12-11